Pricing Log in Create free account
Saturday 17 October 2026 Export PCRX’s income statement to Excel — free account

Pacira BioSciences, Inc.

PCRX Healthcare Drug Manufacturers Specialty & Generic

Pacira BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $726.4 million, up 3.63% from fiscal 2024. In the quarter to June 2026, revenue grew 6.24%, EPS grew 209.1%, free cash flow grew 502.5% and total debt fell 37.4%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

36.35 0.02 +0.06%
Market cap
$1.5B
P/E
104×
Fwd P/E
33.7×
Dividend yield
—
F-score
8/9
Altman Z
2.02
Beneish M
−2.93
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Pacira BioSciences, Inc. (PCRX) Business Profile

Updated before January 2025

Company Overview

Pacira BioSciences, Inc. (NASDAQ: PCRX) is a leading pharmaceutical company specializing in non-opioid pain management and regenerative health solutions. Founded in 2006 and headquartered in Parsippany, New Jersey, Pacira has established itself as a pioneer in the development of innovative products aimed at improving patient outcomes and reducing reliance on opioids for pain management. The company was initially formed as a spin-off from SkyePharma PLC and has since grown into a prominent player in the pharmaceutical industry.

Pacira’s leadership team is composed of seasoned professionals with extensive experience in the healthcare and pharmaceutical sectors. The company’s CEO and Chairman, David Stack, has been instrumental in driving Pacira’s growth and innovation. Under his leadership, the company has expanded its product portfolio and strengthened its position in the market. Other key executives include Charles Reinhart III, the Chief Financial Officer, and Kristen Williams, the Chief Administrative Officer, who collectively contribute to the company’s strategic vision and operational excellence.

Core Business Segments

Pacira BioSciences operates primarily in the field of non-opioid pain management and regenerative health. The company’s product portfolio is centered around innovative solutions designed to address unmet medical needs. The core business segments include:

1. Non-Opioid Pain Management

Pacira’s flagship product in this category is EXPAREL®, a long-acting, non-opioid local analgesic. EXPAREL is used for postsurgical pain management and is designed to provide prolonged pain relief while minimizing the need for opioids. It is widely used in various surgical procedures, including orthopedic, general, and plastic surgeries.

Another notable product is iovera°®, a handheld device that uses cryoneurolysis to deliver targeted pain relief by freezing peripheral nerves. This innovative technology is particularly effective for managing chronic and acute pain, including knee osteoarthritis.

2. Regenerative Health

Pacira has also ventured into regenerative health solutions, focusing on products that promote tissue repair and recovery. This segment includes biologics and other advanced therapies aimed at enhancing patient recovery and improving surgical outcomes.

3. Partnerships and Licensing

In addition to its proprietary products, Pacira collaborates with other pharmaceutical companies and healthcare providers to expand its reach and impact. These partnerships often involve licensing agreements and co-development initiatives that leverage Pacira’s expertise in drug delivery and pain management.

Business Model

Pacira BioSciences operates on a business model that integrates product innovation, strategic partnerships, and a focus on patient-centric solutions. The company generates revenue primarily through the sale of its proprietary products, such as EXPAREL and iovera°, as well as through licensing agreements and collaborations.

Pacira’s approach to business is rooted in its commitment to addressing the opioid crisis by providing effective non-opioid alternatives for pain management. The company invests heavily in research and development (R&D) to create innovative products that meet the evolving needs of patients and healthcare providers. Additionally, Pacira leverages its strong distribution network and strategic partnerships to ensure its products reach a wide audience.

Strategic Direction

Pacira BioSciences is focused on expanding its product portfolio and geographic footprint to drive long-term growth. The company’s strategic priorities include:

  • Product Innovation: Pacira continues to invest in R&D to develop new non-opioid pain management solutions and regenerative health products. The company is also exploring the potential of its existing products for new indications.
  • Market Expansion: Pacira aims to increase its presence in international markets by securing regulatory approvals and forming strategic alliances with global partners.
  • Sustainability Goals: The company is committed to sustainability and aims to reduce its environmental footprint through eco-friendly manufacturing practices and responsible sourcing of raw materials.
  • Digital Transformation: Pacira is leveraging digital technologies to enhance its operations, improve patient engagement, and streamline its supply chain.

Competitive Landscape

Pacira BioSciences operates in a highly competitive market, facing competition from both large pharmaceutical companies and smaller biotech firms. Key competitors include:

  • Heron Therapeutics, Inc.: A biopharmaceutical company specializing in pain management and oncology care.
  • AcelRx Pharmaceuticals, Inc.: Known for its innovative pain management products, including sublingual opioid formulations.
  • Mallinckrodt Pharmaceuticals: A global specialty pharmaceutical company with a focus on pain management and regenerative medicine.
  • Halyard Health (now part of Avanos Medical): Offers a range of non-opioid pain management solutions, including nerve block catheters.

Despite the competition, Pacira differentiates itself through its focus on non-opioid solutions and its commitment to innovation.

Risk Factors

Like any pharmaceutical company, Pacira faces several risks that could impact its business operations and financial performance. Key risk factors include:

  • Market Dependence: A significant portion of Pacira’s revenue comes from EXPAREL, making the company vulnerable to market fluctuations and competitive pressures.
  • Regulatory Challenges: The pharmaceutical industry is heavily regulated, and any delays or failures in obtaining regulatory approvals could hinder Pacira’s growth.
  • Supply Chain Disruptions: The company relies on a global supply chain for raw materials and manufacturing, making it susceptible to disruptions caused by geopolitical events, natural disasters, or pandemics.
  • Litigation Risks: As a pharmaceutical company, Pacira is exposed to potential legal challenges, including patent disputes and product liability claims.

Recent Developments

Pacira BioSciences has made significant strides in recent years, including:

  • EXPAREL Expansion: The company has received regulatory approvals for new indications of EXPAREL, broadening its application in various surgical procedures.
  • Acquisition of MyoScience, Inc.: This acquisition added iovera° to Pacira’s product portfolio, enhancing its capabilities in non-opioid pain management.
  • Collaborations: Pacira has entered into strategic partnerships with healthcare providers and pharmaceutical companies to expand its reach and impact.
  • COVID-19 Response: The company has implemented measures to ensure the safety of its employees and the continuity of its operations during the pandemic.

Investment Considerations

Investors considering Pacira BioSciences should weigh the following strengths and risks:

Strengths

  • Strong focus on non-opioid pain management, addressing a critical healthcare need.
  • Innovative product portfolio with significant growth potential.
  • Experienced leadership team with a proven track record.
  • Commitment to sustainability and corporate responsibility.

Risks

  • Heavy reliance on a single product (EXPAREL) for revenue.
  • Exposure to regulatory and legal challenges.
  • Competitive pressures from other pharmaceutical companies.
  • Potential supply chain disruptions.

Conclusion

Pacira BioSciences, Inc. is a leader in non-opioid pain management and regenerative health, with a strong commitment to innovation and patient-centric solutions. The company’s focus on addressing the opioid crisis and improving surgical outcomes positions it well for future growth. While there are risks associated with market dependence and regulatory challenges, Pacira’s strengths in product innovation and strategic partnerships make it a compelling investment opportunity. As the company continues to expand its product portfolio and geographic footprint, it is poised to maintain its leadership position in the pharmaceutical industry.